Try our Advanced Search for more refined results
Dolin v. Smithkline Beecham Corporation, et al
Case Number:
1:12-cv-06403
Court:
Nature of Suit:
365(Personal Inj. Prod. Liability)
Judge:
Firms
- Dentons
- Husch Blackwell
- King & Spalding
- Perl & Goodsnyder
- Phillips Lytle
- Pietragallo Gordon
- Rapoport Law Offices
- Swanson Martin
- The Horwitz Law Group
- Troutman Pepper
- Wiedner & McAuliffe
- Williams & Connolly
- Wisner Baum
Companies
Sectors & Industries:
-
November 20, 2015
GSK Loses Bid To Nix Experts Of Reed Smith Atty's Widow
GlaxoSmithKline was hit with a setback Friday when an Illinois federal judge rejected its motions to exclude expert testimony for the widow of a Reed Smith LLP attorney who had committed suicide after taking a generic version of its antidepressant Paxil.
-
October 13, 2015
GSK Says FDA Orders Nix Reed Smith Atty's Widow's Claims
GlaxoSmithKline has continued its efforts to defeat a suit in Illinois federal court by the widow of a Reed Smith LLP partner who committed suicide after taking a generic version of its antidepressant Paxil, arguing that her claims are preempted because Paxil's label followed the U.S. Food and Drug Administration's requirements.
-
October 08, 2015
Reed Smith Atty's Widow Fights GSK's Bid To Nix Suicide Suit
The widow of a Reed Smith LLP partner who killed himself after taking a generic version of GlaxoSmithKline PLC's antidepressant Paxil on Wednesday fought the drugmaker's summary judgment motion, arguing that there is plenty of evidence that it manipulated data to mask the medication's potential suicide risk.
-
October 07, 2015
GSK Rips 'Junk Science' By Reed Smith Atty Widow's Expert
GlaxoSmithKline PLC has continued to fight the inclusion of testimony by an expert for the widow of a Reed Smith LLP partner who killed himself after taking a generic version of its antidepressant Paxil, accusing the expert of relying on "junk science" in attempting to link the drug to suicides.
-
September 03, 2015
GSK Fights To Block Expert For Reed Smith Atty's Widow
GlaxoSmithKline PLC told an Illinois federal court Wednesday to exclude the expert introduced by the widow of a Reed Smith LLP partner who allegedly committed suicide after taking a generic version of its antidepressant Paxil, claiming he has no reliable scientific methodology to support his claims.
-
August 05, 2015
GSK Wants More Info On Expert For Widow Of Reed Smith Atty
GlaxoSmithKline PLC continued its fight for documents related to the expert witness for the widow of a Reed Smith attorney who committed suicide after taking a generic version of its antidepressant Paxil, arguing Tuesday that she must submit a list of privileged documents she seeks to keep from its grasp.
-
June 22, 2015
Expert Must Show Docs In Reed Smith Atty Paxil Suicide Suit
An Illinois federal judge ordered a psychiatrist on Friday to turn over documents related to a medical board investigation in a suit by the widow of a Reed Smith LLP attorney against GlaxoSmithKline PLC over whether a generic version of its Paxil antidepressant caused the attorney to kill himself.
-
April 30, 2015
GSK Wants Info On Expert For Reed Smith Atty's Wife
GlaxoSmithKline PLC told an Illinois federal judge Wednesday that the widow of a former Reed Smith LLP partner claiming a generic version of GSK's antidepressant Paxil caused his suicide must provide more information on an expert who said the company is out to get him.
-
April 27, 2015
Reed Smith Atty's Widow Slams GSK's Bid To Delay Trial
The widow of a former Reed Smith LLP partner who allegedly committed suicide as a result of taking a generic version of the antidepressant Paxil told an Illinois federal judge on Friday that GlaxoSmithKline PLC has unreasonably attempted to push the trial's start date into 2016.
-
November 18, 2014
Reed Smith Atty's Widow Pushes For GSK Docs In Paxil Fight
The widow of a Reed Smith LLP partner, who is suing GlaxoSmithKline PLC over a generic version of its antidepressant Paxil that her husband took before his suicide, pushed Monday for documents including GSK's communications with generics maker Mylan about the drug's labeling.